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disease (COPD), exacerbated COPD, smokers without apparent COPD, and healthy
volunteers should be of interest for pathophysiological and therapeutic reasons.
Methods including lavage, biopsy and sputum have been employed to investigate
cytokines in the lung. For asystematic comparison, exhaled breath condensate (EBC)
appears to be well suited.
We investigated healthy volunteers, smokers without apparent COPD,
stable and exacerbated COPD patients (7 inhalative steroids) and finally
those whose exacerbation made mechanical ventilation inevitable, for a
more complete picture of inflammatory cytokines in COPD. We chose EBC
because it is non-invasive and can be used repeatedly in spontaneous breathing
individuals and during mechanical ventilation. EBC cytokines (IL-1b; IL-6, IL-8, IL-10,
IL-12p70, TNF-a) were assayed from a single sample using a multiplex array
test kit.Elsevier Ltd. All rights reserved.
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C. Gessner et al.1230We observed a significant increase of all cytokines in acute exacerbation
compared to stable COPD, smokers, and volunteers. Stable COPD and volunteers
exhibited only small differences in cytokine pattern with respect to IL-1b and IL-12
ðPo0:01Þ: Smokers had increased levels of all investigated cytokines ðPo0:01Þ
compared to non-smokers and, with the exception of IL-1b; to stable COPD. Inhaled
steroids resulted in reduced levels of IL-1b; IL-6, IL-8, IL-10, and IL-12 (all: Po0:01)
in stable COPD (all: ex-smokers) with dose dependency for IL-8, IL-1b and IL-12.
EBC analysis successfully characterized important differences in stable COPD
compared to exacerbation or smoking and non-smoking healthy individuals.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is
characterized by airflow obstruction due to chronic
bronchitis and/or emphysema1 which is progressive
and associated with an abnormal inflammatory
response of the lung. The final result of this process
is destruction and loss of lung parenchyma. Various
methods have been employed to investigate and
possibly quantify inflammation in COPD. Among
them invasive methods such as biopsy of the
bronchial walls2,3 as well as bronchoscopy and
bronchoalveolar lavage (BAL) with subsequent
examination of cells and soluble markers.4–8 In-
duced sputum, a less invasive method, has been the
source for many investigations aimed at describing
inflammation.9–13 Exhaled breath condensate (EBC)
constitutes another, entirely non-invasive method
which has been used for the same purpose.14–18
Different stages and variations of the process called
COPD were investigated, with a majority of the
studies investigating stable disease9,10,12,16
although in some cases acute exacerbations of
COPD (AECOPD) were also studied.19–22 The most
severe and acute form of COPD, AECOPD that leads
to ICU treatment and the need for invasive
mechanical ventilation has also been studied by
this technique with respect to pH, cytokines and
nitrite.18 The different situations of exacerbation
of COPD as well as stable disease were variably
compared to either healthy volunteers and/or
smokers without apparent signs of COPD.6–8,17 In
this study we wanted to characterize the cytokine
pattern of inflammation in stable and exacerbated
COPD (stable COPD, AECOPD with general ward
treatment [AECOPD-GW], AECOPD with ICU treat-
ment [AECOPD-ICU]) and compare it to healthy
volunteers as well as smokers without apparent
COPD. EBC was used to investigate the cytokine
patterns, because this material is non-invasive and
sampling does not lead to any alteration of the
inflammatory situation of the airways. In this study
EBC cytokine measurement proofed to be useful in
estimating the inflammatory status of the differentpatient groups. Volunteers, smokers, stable COPD
patients and exacerbated COPD patients all ex-
hibited significant differences. The understanding
of these patterns may facilitate therapeutic deci-
sions.Methods
Study subjects and clinical scores
EBC was collected from:(a) ICU patients with life-threatening exacerbation
of COPD on mechanical ventilation (AECOPD-
ICU),23 n ¼ 11:(b) Patients with severe and very severe exacer-
bated COPD with the need for hospital admis-
sion in a general ward (AECOPD-GW),23 n ¼ 34:(c) Patients with known and stable COPD (stable
COPD), n ¼ 40: (Stable COPD was defined by the
lack of symptoms typical for an acute exacer-
bation and no need for a change in medication
for at least 8 weeks prior to presentation.)(d) Healthy smoking volunteers (HS), n ¼ 21:
(e) Healthy non-smoking volunteers (VOL), n ¼ 24:Patient’s characteristics are depicted in Table 1.
Patients on mechanical ventilation were included in
this investigation at 8–48 h of ventilation. Mechan-
ical ventilation was performed according to guide
lines for protective ventilation with a tidal volume
at 6ml/kg ideal body weight.24 Ventilated patients
fulfilled criteria described by Burge and co-work-
ers.23 EBC of patients with AECOPD was collected
before therapy at the time of diagnosis. All
AECOPD-GW patients exhibited criteria for admis-
sion to a hospital as has been suggested23:
respiratory rate 425/min; pulse rate 4110/min;
PaO2o8 kPa; abnormal chest radiograph; serious
concomitant disease; altered mental state; living
alone. All AECOPD patients (ICU and GW) were
treated with i.v. antibiotics. EBC collection was
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Table 1 Patient’s characteristics.
Patients VOL HS Stable COPD AECB-GW AECB-ICU
Total number 24 21 40 34 11
Age (mean7SD) 54.7710.5 59.0712.2 60.3715.8 62.1712.3 62.779.6
Sex
Male 13 12 27 24 6
Female 11 9 13 10 5
Smoking statusy Non-smoker Smoker Ex-smoker Ex-smoker Ex-smoker
Pack years 0 2675 3079 2877 2775
FEV1 (l)
z 3.7970.46 3.3870.58 1.3370.60 1.3370.59 1.2170.38
FVC (l)z 4.1470.49 3.8970.58 2.5370.96 2.2870.82 2.3670.76
FEV1/FVC (%)
z 91.472.50 86.774.46 51.977.61 57.279.36 52.678.11
PaO2 (kPa)
y 10.0970.40 9.4470.40 7.3770.46 6.6370.28 5.3670.61
PaCO2 (kPa)
y 5.1570.29 5.4070.31 5.8470.31 6.5870.24 8.5870.63
Protein in EBC (mg/ml) (mean7SD) 13.978.9 13.475.5 11.574.4 10.775.3 14.479.1
ICSz therapy
Yes 0 0 21 20 0
No 24 21 19 14 11
All data are shown as mean 7SD.
P40.05 (no significant difference between investigated groups) in ANOVA test.
ySmoking was defined as current smokers or ex-smokers that discontinued smoking no longer than 12 month, non-smoking as
no smoking longer than 1 year.
zResults were measured after AECB.
yResults were measured at time of hospitalization.
zICS: inhalative corticosteroid.
Exhaled breath condensate cytokine in COPD 1231performed between 8 and 36 h following hospitali-
zation. At the time of EBC collection corticoster-
oids had not yet been given. AECOPD diagnosis was
based on criteria described by Anthonisen25: pre-
sence of at least one of the following three major
symptoms: increase in dyspnoe, sputum volume
increase, sputum change to purulence and at least
one of the following minor symptoms: cough,
wheeze, sore throat, nasal discharge, fever. All
patients with stable COPD, AECOPD-GW, and
AECOPD-ICU were nonsmokers for at least 1 year
according to their own saying.
Lung function was performed on the day of EBC
collection in all stable patients, within 1 week in
AECOPD-GW patients and within 10 days following
extubation in AECOPD-ICU patients. Capillary blood
gas analysis was performed on all patients within
the first few hours after admission.
All COPD patients were staged according to
current guidelines (GOLD), (1 update 2003) as stage
III COPD or stage IV COPD. None of the patients in
this series was treated with an oral steroid. All
patients were on oral (theophylline) and inhaled
therapy (LABA and/or long acting anticholinergic
and/or inhaled corticosteroids (ICs)) according to
the guidelines. All patients were regularly seen by
pulmonary specialists. Approval for this investiga-
tion was obtained from the ethics committee of the
University of Leipzig.EBC collection and markers
EBC was collected by inserting a special conduit
(FILT lung and Chest Diagnostics Ltd., Berlin,
Germany) for the EcoScreens breath condensate
collecting device (ViaSys, Hoechberg, Germany)
into the expiratory limb of the ventilator tubing
directly after the Y-shaped connecting piece for a
20min time period. Humidification of inspiratory
gas was achieved using heat humidifiers.
EBC from spontaneously breathings was similarly
collected for 20min with the EcoScreens system as
previously described.26
All EBC samples were examined for amylase
activity (alpha-Amylase ESP1491300 kit; detection
limit 0.05 mmol/l s; Boehringer Mannheim, Ger-
many) in order to exclude contamination by saliva.
Protein concentration in EBC was measured using
the Micro BCA Protein Assay (Pierce, Rockford USA).Bronchoalveolar lavage (BAL)
When BAL was scheduled for microbiological reasons in
AECOPD patients, an aliquot (2ml) was taken for the
comparison of cytokines in BAL fluid (BALF) and EBC. A
comparison of BALF and EBC was thereby achieved in
14 cases. In all cases, EBC collection was performed
prior to bronchoscopy. BAL was done according to
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C. Gessner et al.1232published guidelines27 (5 20ml aliquots). The cell
free supernant was used for further analysis.Cytometric bead array
A multiplex fluorescent bead immunoassay (cyto-
metric bead array [CBA] Becton Dickinson, San
Jose, CA, USA) has been adapted to analysis in
breath condensate to detect cytokine concentra-
tions. A mixture of six bead populations with
distinct fluorescence intensities and coated with
capture antibodies specific for IL-8, IL-1b; IL-6, IL-
10, TNF-a; and IL-12p70 proteins were incubated
with 2ml of lyophilized breath condensate recon-
stituted with 50 ml of ddH2O (duplicate samples
were prepared). Cytokines in EBC samples and
recombinant standards bound to capture beads
were detected by PE-conjugated detection anti-
bodies in a flow cytometer (FACS CaliburTM, Becton
Dickinson). Effects of cryoconservation, lyophiliza-
tion, and reduction of reagent amounts as well as
requirements to buffer composition were investi-
gated in a group of 9 samples in order to ensure
correct detection of cytokines by this commercially
available system: defined cytokine concentrations
were dissolved in water and measured before and
after cryoconservation and lyophilization. A loss of
10.6% of activity was observed. By adding 1% of BSA
this loss was reduced to 1.8%.
Mean intra-assay reproducibility and inter-assay
reproducibility were 92.8% (IL-8: 89.5%; IL-1b:
94.5%; IL-6: 90.7%; IL-10: 96.5%; TNF-a: 91.6%; IL-
12: 93.9%) and 87% (IL-8: 80.6%; IL-1b: 85.7%; IL-6:
90.4%; IL-10: 92.7%; TNF-a: 88.9%; IL-12: 83.8%),
respectively.Statistical analysis
Statistical analysis was performed with the SPSS
software package (SPSS Inc., Chicago, USA). LinearTable 2 Detection rates of cytokines in EBC.
Marker Detection rates for cytokines
VOL HS Stable COPD
d/nd (%) d/nd (%) d/nd (%)
IL-8 14 (58)/10 (42) 19 (90)/2 (10) 31 (77)/9 (23
IL-1b 19 (79)/5 (21) 21 (100)/0 (0) 39 (97)/1 (3)
IL-6 11 (46)/13 (54) 20 (95)/1 (5) 15 (37)/25 (6
IL-10 13 (54)/11 (46) 19 (90)/2 (10) 31 (77)/9 (23
TNF-a 16 (67)/8 (33) 20 (95)/1 (5) 33 (82)/7 (18
IL-12p70 19 (79)/5 (21) 21 (100)/0 (0) 37 (92)/3 (8)
d, cytokine detectable; nd, cytokine not detectable.regression analysis was applied to investigate the
correlation of cytokine levels in EBC and BALF.
Comparison of patient groups (three or more) was
performed by Kruskal–Wallis test and Mann–Whit-
ney test. Data in box blots are median 725/75%
(box) and 5/95% confidence intervals, with outlying
data points indicated as closed circles. Statistical
significance was accepted at the 5% level.Results
Patients’ characteristics
Patient characteristics are listed in Table 1.
General exhaled breath condensate
characteristics
None of the condensate samples exhibited amylase
concentrations measurable with the assay used.
Therefore a relevant saliva contamination can be
excluded because amylase concentration in saliva
is proximally 10,000 times higher than those in EBC
with respect to detection limit of assays.28,29
Total EBC protein concentration was regularly
measured. Results are shown in Table 1. There was
no significant difference in any of the subgroups
analyzed ðP ¼ 0:27Þ:
Inflammatory cytokines in EBC
The rates of detection of the various cytokines in
all of the patient subgroups are listed in Table 2. In
AECOPD-ICU and AECOPD-GW patients all cytokine
levels were considerably higher and cytokines were
more often detectable than in patients with stable
COPD, healthy smokers or healthy volunteers (Fig.
1, Table 2). Cytokines in relation to protein in EBC
showed comparable results shown in Fig. 2.AECOPD-GW AECOPD-ICU All patients
d/nd (%) d/nd (%) d/nd (%)
) 34 (100)/0 (0) 11 (100)/0 (0) 109 (84)/21 (16)
34 (100)/0 (0) 11 (100)/0 (0) 124 (95)/6 (5)
3) 33 (97)/1 (3) 10 (91)/1 (9) 89 (68)/41 (32)
) 34 (100)/0 (0) 11 (100)/0 (0) 108 (83)/22 (17)
) 34 (100)/0 (0) 11 (100)/0 (0) 114 (88)/16 (12)
34 (100)/0 (0) 11 (100)/0 (0) 122 (94)/8 (6)
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Figure 1 IL-8, IL-1b; IL-6, IL-10, TNF-a; and IL-12p70 levels in EBC of patients at ICU with life-threatening exacerbation
of COPD on mechanical ventilation (AECOPD-ICU: n ¼ 11), patients with severe and very severe exacerbated COPD with
the need for hospital admission in a general ward (AECOPD-GW: n ¼ 34), patients with known and stable COPD (stable
COPD: n ¼ 40), healthy smoking volunteers (HS: n ¼ 21), and healthy non-smoking volunteers (VOL: n ¼ 24). Results are
median 725/75% (box) and 5/95% confidence intervals, with outliers indicated as closed circles.
Exhaled breath condensate cytokine in COPD 1233Differences between stable COPD and healthy
smokers were observed in all cytokines investigated
with the exception of IL-1b: Healthy smokers
showed significantly increased levels for all cyto-
kines compared with healthy volunteers. For stable
COPD and healthy volunteers differences were only
observed for IL-1b and IL-12p70 (Figs. 1 and 2).
Subgroup analysis of COPD stage III versus COPD
stage IV in both the AECOPD as well as in the stable
COPD patient groups did not reveal significantdifferences with respect to cytokines analyzed
(data not shown).Correlation of EBC cytokines with lung
function or ventilatory parameters
Results of lung function as well as blood gas analysis
are shown in Table 1 for the following parameters:
FEV1, FVC, FEV1/FVC, PaO2, and PaCO2. There was
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Figure 2 IL-8, IL-1b; IL-6, IL-10, TNF-a; and IL-12p70 levels in EBC in relation to protein in EBC of patients with life-
threatening exacerbation of COPD on mechanical ventilation (AECOPD-ICU: n ¼ 11), patients with severe and very
severe exacerbated COPD with the need for hospital admission in a general ward (AECOPD-GW: n ¼ 34), patients with
known and stable COPD (stable COPD: n ¼ 40), healthy smoking volunteers (HS: n ¼ 21), and healthy non-smoking
volunteers (VOL: n ¼ 24). Results are median725/75% (box) and 5/95% confidence intervals, with outliers indicated as
closed circles.
C. Gessner et al.1234no strong, significant correlation observed between
lung function parameters VC, Rtot, FEV1, FVC, FEV1/
FVC, TLC, RV, PaO2, and PaCO2 and the level of
cytokines in EBC of either all patients or any of the
subgroups. This same result was also true for all theparameters of ventilation examined in this study:
positive end expiratory pressure (6.7mbar73.4),
peak inspiratory pressure (20.6mbar73.3), tidal
volume adapted to ideal body weight (6.3ml/kg
body weight71.0), expiratory minute volume
ARTICLE IN PRESS
Exhaled breath condensate cytokine in COPD 1235(9.8 l/min72.5) and breathing frequency
(21.574.5) when correlated to cytokine levels in
ventilated patients.Influence of inhaled corticosteroid in COPD
patients at cytokines in EBC
Stable COPD patients ðn ¼ 40Þ and patients with
AECOPD-GW ðn ¼ 34Þ were evaluated for the
influence of ICS on the level of cytokines in EBC.Figure 3 EBC cytokines in patients with severe and very sever
in a general ward (AECOPD) with ðn ¼ 18Þ and without ðn ¼ 1
(stable COPD) with ðn ¼ 21Þ and without ðn ¼ 19Þ ICS therapy
with outliers indicated as closed circles).We found lower levels for IL-1b; IL-6, IL-8, IL-12,
and IL-10 (all: Po0:01) but not for TNF-a in patients
with stable COPD on ICS ðn ¼ 21Þ compared with
stable COPD patients without ICS (n ¼ 19; Fig. 3).
ICS-dose dependence (lower dosep1000 mg; higher
dose 41000 mg/day) was recognized for IL-8, IL-1b
and IL-12 (Fig. 4). In contrast to these results,
patients with AECOPD exhibited no difference in
cytokine levels depending on the use of ICS (Fig. 3).
Although a lower level of EBC cytokines was
prominent in stable COPD patients on ICS, noe exacerbated COPD with the need for hospital admission
1Þ ICS therapy and patients with known and stable COPD
(median 725/75% [box] and 5/95% confidence intervals,
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Figure 4 Cytokine levels in EBC of stable COPD patients on p1000mg ðn ¼ 10Þ; and 41000 ðn ¼ 11Þ of daily
beclomethasone equivalent of inhaled steroid (median 725/75% [box] and 5/95% confidence intervals, with outliers
indicated as closed circles).
C. Gessner et al.1236change in lung function parameters was apparent in
comparison with stable COPD patients without ICS.
Correlation of cytokine levels in BALF and
EBC
The correlation of BALF ingredients with the same
molecules in EBC is largely unknown. We found no
significant correlation between cytokine levels in
BALF and those in EBC (Table 3). However the
results were not equal for all of the cytokines
investigated and clearly the correlation was closerfor IL-12p70 (r ¼ 0:52; P ¼ 0:06; Fig. 5) than for any
of the remaining cytokines investigated. A larger
number of samples might well have demonstrated a
significant correlation in this case and possibly also
for IL-6 and IL-10.Discussion
This study was aimed at characterizing infla-
mmation by analyzing cytokine profiles in
healthy individuals, smokers, stable COPD, acute
ARTICLE IN PRESS
Table 3 Correlation of EBC cytokines and BALF
cytokines in a subgroup of 14 patients.
Marker Correlation of EBC and BALF
R P-value
IL-8 0.03 0.93
IL-1b 0.06 0.83
IL-6 0.40 0.15
IL-10 0.41 0.15
TNF-a 0.21 0.46
IL-12p70 0.52 0.06
18
BA
L 
IL
-1
2p
70
 (p
g/m
l)
16
14
12
10
8
6
4
2
0
0 100 200 300 400 500
EBC IL-12p70 (pg/ml)
Figure 5 Correlation of IL-12p70 in EBC with concentra-
tion in BAL (r ¼ 0:52; P40:06) in a subgroup of 14
patients.
Exhaled breath condensate cytokine in COPD 1237exacerbation without and with the need for
mechanical ventilation. We chose to measure
cytokine profiles in EBC because this material is
acquired non-invasively. Investigating a potential
influence of ICS on the cytokine profiles was a
secondary aim of our study.
Chronic inflammation, although different to that
in asthma is the predominant feature of COPD. The
nature of this inflammatory process has been
thoroughly investigated by, e.g. invasive methods
such as biopsies and bronchoscopy.6,8 Several
investigators have relied upon induced sputum as
a source for monitoring of inflammation.4,19,30
Detection of cytokines in EBC has only been used
in one study of COPD patients.16 This is the first
study comparing a systematic profile of cytokines in
a spectrum of healthy volunteers, smokers without
COPD, stable COPD patients and patients with
AECOPD using EBC.A prominent finding of this study is the order of
magnitude in differences of cytokine levels of COPD
patients with acute exacerbations in comparison
with either stable COPD patients, healthy smokers
or non-smoking volunteers. This difference in
magnitude relates to all of the cytokines examined.
A similarly strong increase of cytokine levels,
approx. 15 fold in this study, was only paralleled
in an analysis of Nys et al. in which a 5–25 fold
increase in IL-1b and IL-8 was observed in BALF of
patients with acute lung injury with pneumonia
versus patients with acute lung injury without
pneumonia.31 A much smaller difference was
observed in investigations using induced sputum
where AECOPD-GW versus stable COPD resulted in
an IL-6 increase of approx. 1.5 fold32 or an IL-8
increase of 2 fold and a TNF-a increase of 4 fold.22
EBC cytokine analysis using the bead array used
here appears to be very sensitive in picking up large
differences in cytokine levels in acute inflammation
compared to more chronic inflammation. This of
course would be a prerequisite of any standard tool
for monitoring inflammation.
Cytokines expressed in relation to protein con-
centration in EBC as a means of standardization
showed absolutely comparable results with regard
to the differences between subgroups. Protein
concentration in EBC has been suggested to be
one of the potential ways to standardize concen-
trations in EBC. However, no reliable way of
standardization has yet been agreed upon. We
therefore decided to present the raw cytokine
concentrations as measured in EBC in this paper.
Much smaller magnitudes of cytokine levels were
observed in clinically stable and clinically healthy
situations. However, volunteers were different
from smokers with respect to all cytokines demon-
strating that smoking without any sign of COPD does
induce an inflammatory lesion. In BALF a similar
subset of cytokines was analyzed before and did not
result in significant differences between stable
COPD patients, smokers and non-smokers at com-
parable group sizes.33 Although not significant, the
relative levels observed in this study fit well to our
data. An IL-6 increase (2 fold) due to smoking
comparable to the one described in our study was
previously reported in EBC.34 We also observed an
increase in IL-8 in smokers compared with non-
smokers. In contrast IL-8 was not different between
these two groups in a study using BALF to analyze
neutrophil chemokines in smokers and non-smo-
kers.7
Cytokine levels in stable COPD patients who were
all seen by pulmonary specialists and who were
treated according to current guidelines were rather
low in comparison with those of smokers and
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C. Gessner et al.1238volunteers. A significant difference between stable
COPD and healthy volunteers was only seen for IL-
1b and IL-12. In fact, in stable COPD the level of
inflammatory cytokines appeared to be lower than
in smokers possibly due to the fact that all patients
with stable COPD had quit smoking at least 1 year
ago. A study that has found elevated levels of, e.g.
IL-8 in BALF of smokers5 is not really comparable to
any of our groups, because all COPD patients were
smokers whereas in this study all COPD patients
were ex-smokers and smokers were clinically
apparent. Another explanation for the small differ-
ence in cytokine levels between stable COPD
patients and healthy volunteers might have been
therapeutic intervention. Because steroids have an
influence on cytokine levels in many systems we
evaluated the effect of ICS on cytokine levels in
stable COPD and AECOPD-GW patient subgroups. In
stable COPD ICS therapy in this study was corre-
lated with decreased levels of IL-1b; IL-8, IL-6, IL-
10 and IL-12 but not TNF-a: Other authors have not
observed an ICS induced effect on IL-8, MMP-1,
MMP-9, SLIP, and TIMP-1 in induced sputum35
indicating again, that EBC analysis of cytokines
may be a method with increased sensitivity. In fact
the effect of ICS in COPD is a matter of ongoing
debate. From this study it can be concluded, that
there is definitely an effect of ICS on cytokines in
EBC and this effect can even be underscored by
demonstrating an ICS-dose dependency for IL-1b;
IL-8 and IL-12. Patel and coworkers similarly found
lower IL-6 and IL-8 concentrations in supernatant of
human bronchial epithelial cells harvested from
biopsies of stable COPD patients and a negative
correlation of at least IL-6 with the ICS dose.2 The
effect of dexamethasone on basal cytokine release
by alveolar macrophages varied in another study
between smokers and COPD patients.4 Dexametha-
sone 105 M resulted in a significant reduction in
both smoking COPD patients (approx. 45% reduction
of basal GM-CSF release in macrophages) and
smokers without COPD (approx. 57% reduction). In
contrast, dexamethasone 105 M did not result in a
significant reduction of the strongly increased IL-8
release in smoking COPD patients, but did reduce
the much lower basal release of IL-8 in smokers
without COPD by approx. 30%.4 Further work of Ito
and coworkers demonstrated a significant differ-
ence in the effect of dexamethasone 106 M on IL-
1b induced release of IL-8 and TNF-a between
smokfers (without COPD) and non-smokers36: dex-
amethasone failed to reduce the stimulated release
of both cytokines in smokers. This and experiments
aiming at the activity and expression of the enzyme
histone deacetylase (HDAC) has generated the
hypothesis, that smoking inhibits HDAC expressionand promotes cytokine expression and the lack of
steroid responsiveness.37 It was suggested that
even in COPD patients that have stopped smoking,
this mechanism might continue. Our findings with
COPD patients that all were ex-smokers appear to
argue against that assumption. Our findings in fact
seem to fit well with the clinical impression that
inhaled steroids do reduce the frequency of COPD
exacerbations38 and that lower levels of cytokines
are related to less frequent COPD exacerbations.19
However, there was no relation of IL-8 level in
induced sputum and exacerbation frequency in
another investigation39 The significance of this
finding will have to be further investigated. In
AECOPD-GW patients, no impact of ICS on cytokine
levels was observed, but cytokine levels were much
higher as mentioned before and the small doses of
inhaled steroids might not be enough to influence
this level of inflammation. Oral steroids have
proven use in this situation.
A methodological question we wanted to answer
in this study concerned the correlation of cytokine
levels of EBC with BAL fluid of the same patient. We
did not find any significant correlation of cytokine
levels in EBC compared with BALF although the
numbers varied for each cytokine and significance
seemed within reach for IL-12p70. This is in some
contrast to another marker, nitrite, for which we
previously described a significant but not very
strong correlation between EBC and BALF.40 We
cannot offer a good explanation for the dissimilar
behavior of different cytokines. Instead we postu-
late that a correlation of ingredients of EBC and
BALF will have to be demonstrated for each
ingredient separately.
An increasing number of papers indicate the
usefulness of EBC in respiratory medicine. An ERS
statement on this subject is currently in prepara-
tion. For the purpose of estimating the extent of
inflammation of the airways/lung in COPD, EBC
seemed to perform well and might enable physi-
cians to monitor the disease and rationally follow
therapy.
We conclude that AECOPD-GW and AECOPD-ICU
exhibit similar strong increases in cytokine levels in
COPD patients. Stable COPD (ex-smokers) and
volunteers were similar with respect to cytokine
patterns with the exception of elevated IL-1b and
IL-12. Smokers have increased levels of all cyto-
kines when compared to non-smokers. Inhaled
steroids resulted in reduced levels of IL-1b; IL-6,
IL-8, IL-10 and IL-12 in stable COPD (ex-smokers)
with dose dependency demonstrated for IL-1b; IL-8
and IL-12. EBC therefore appears to be able to
characterize important differences in various COPD
patient groups.
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